Articles published by Biogen Inc.
Biogen Appoints Jane Grogan as Head of Research
September 06, 2023
From Biogen Inc.
Via GlobeNewswire
Tickers
BIIB
FDA Grants Traditional Approval for LEQEMBI® (lecanemab-irmb) for the Treatment of Alzheimer’s Disease
July 06, 2023
From Biogen Inc.
Via GlobeNewswire
Tickers
BIIB
Biogen Announces Changes to Its Board of Directors
June 12, 2023
From Biogen Inc.
Via GlobeNewswire
Tickers
BIIB
Health Canada Accepts New Drug Submission for Lecanemab as Treatment for Early Alzheimer’s Disease
May 15, 2023
From Biogen Inc.
Via GlobeNewswire
Tickers
BIIB
Biogen Appoints Adam Keeney as Head of Corporate Development
April 04, 2023
From Biogen Inc.
Via GlobeNewswire
Tickers
BIIB
Eisai Presented New Analyses of ARIA and QOL on Lecanemab in Clarity AD at the AD/PD™ 2023 Annual Meeting
March 30, 2023
From Biogen Inc.
Via GlobeNewswire
Tickers
BIIB
Biologics License Application for Lecanemab Designated for Priority Review by China National Medical Products Administration
February 27, 2023
From Biogen Inc.
Via GlobeNewswire
Tickers
BIIB
Lecanemab Receives Priority Review Status in Japan
January 29, 2023
From Biogen Inc.
Via GlobeNewswire
Tickers
BIIB
FDA Accepts Biogen Biologics License Application for BIIB800, A Biosimilar Candidate Referencing ACTEMRA® (tocilizumab)
December 09, 2022
From Biogen Inc.
Via GlobeNewswire
Tickers
BIIB
European Medicines Agency Accepts Tofersen Marketing Authorization Application to Treat Rare, Genetic Form of ALS
December 05, 2022
From Biogen Inc.
Via GlobeNewswire
Tickers
BIIB
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.